Skip to main content
Oxford University Hospitals NHS Foundation Trust
Rheumatology

This site is best viewed with a modern browser. You appear to be using an old version of Internet Explorer.

Profile of Professor Peter Taylor

Professor Peter Taylor
Full name
Professor Peter C Taylor, MA, BM, BCh, PhD, FRCP, FRCPE
Job title
Norman Collison Professor of Musculoskeletal Sciences
Special interests
Rheumatoid arthritis, ankylosing spondylitis and early inflammatory arthritis

Professor Taylor holds the Norman Collison chair of musculoskeletal sciences at the University of Oxford and is a Fellow of St. Peter’s College, Oxford. He is the Director of Clinical Sciences at the Arthritis Research UK and NIHR clinical trials unit at the Botnar Research Centre and Kennedy Institute of Rheumatology within the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences. He was formerly Professor of Experimental Rheumatology at the Kennedy Institute of Rheumatology Division, Imperial College London and Dean of the Charing Cross campus.

Professor Taylor studied pre-clinical medical sciences at Gonville and Caius College at the University of Cambridge and his first degree was in Physiology. He subsequently studied clinical medicine at the University of Oxford and was awarded a PhD degree from the University of London for studies on pathogenesis of arthritis. In the summer of 2015 he was appointed medical director of the National Rheumatoid Arthritis Society, an outstanding patient led charity that works to support patients with rheumatoid arthritis and juvenile inflammatory arthritis.

Professor Taylor chairs the UK government and NIHR Translational Research Partnership in rheumatology that brings together the UK's leading academic and clinical centres for experimental medicine and translational research into a ready-formed partnership of Universities and NHS hospitals. He also chairs the regional Academic Health Sciences Network rheuamtology group and was nominated as a distinguished member of the British Society for rheumatogy in 2016.

Professor Taylor has over twenty years experience in clinical trial design and international leadership in studies of biologic and small molecular therapies in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis including the earliest seminal trails of anti-TNF and anti-IL-6 receptor therapy. His research expertise is in mechanisms sustaining inflammation and clinical trials of new therapies with development of novel outcome measurements for application in assessment of response to therapy including ultrasonographic and high-field magnetic resonance imaging technology. In experimental medicine studies, Professor Taylor employs targeted therapies as probes of pathogenesis to investigate the in vivo biology of the target in the pathobiology of the disease phenotype under investigation. His interest in novel outcome measures also includes new tools for the personalised assessment of well-being which can be used adjunctively to clinical outcome measures in informing management decisions.

Professor Taylor has specialist clinical interests in including rheuamtoid and other inflammatory arthritis, especially early inflammatory arthritis, and leads the early inflammatory arthritis service. Early intervention leads to the best outcomes. But holistic care is especially important such that the service aims to treat not only the disease but more importantly, the person who has the disease. The early arthritis service benefits from access to a multidiciplinary team.